Emerging drugs for the treatment of knee osteoarthritis
作者： Shirley Pei-Chun Yu , David John Hunter , None
DOI: 10.1517/14728214.2015.1037275
关键词:
摘要: Introduction: Osteoarthritis (OA) is the most prevailing form of joint disease, with symptoms affecting 10 – 12% adult population a projection 50% increase in prevalence next two decades. The disease characteristics are defined by articular cartilage damage, low-grade synovial inflammation and hypertrophic bone changes, leading to pain functional deterioration. To date, available treatments limited their efficacy have associated toxicities. No structural modification agents been approved regulatory agencies for this indication.Areas covered: We reviewed drugs Phase II III OA structure modification. Different aspects divided into targets inflammatory pathway, catabolism anabolism, subchondral remodeling.Expert opinion: Further insight pathophysiology will allow development novel target classes focusing on link between symptomatology a...
informahealthcare.com参考文章(136)
Geoffrey Burnstock, Introduction to Purinergic Signalling in the Brain Advances in Experimental Medicine and Biology. ,vol. 986, pp. 1- 12 ,(2013) , 10.1007/978-94-007-4719-7_1
Gürler D, Say F, Malkoc M, Bülbül M, Yener K, Platelet-rich plasma injection is more effective than hyaluronic acid in the treatment of knee osteoarthritis. Acta Chirurgiae Orthopaedicae Et Traumatologiae Cechoslovaca. ,vol. 80, pp. 278- ,(2013)
S Meini, P Cucchi, C Catalani, F Bellucci, S Giuliani, CA Maggi, Bradykinin and B2 receptor antagonism in rat and human articular chondrocytes British Journal of Pharmacology. ,vol. 162, pp. 611- 622 ,(2011) , 10.1111/J.1476-5381.2010.01062.X
Tim D Spector, Philip G Conaghan, J Christopher Buckland-Wright, Patrick Garnero, Gary A Cline, John F Beary, David J Valent, Joan M Meyer, Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173] Arthritis Research & Therapy. ,vol. 7, pp. 1- 9 ,(2005) , 10.1186/AR1716
Mark T. Brown, Frederick T. Murphy, David M. Radin, Isabelle Davignon, Michael D. Smith, Christine R. West, Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial. Arthritis & Rheumatism. ,vol. 65, pp. 1795- 1803 ,(2013) , 10.1002/ART.37950
Mugdha Gore, Alesia B. Sadosky, Douglas L. Leslie, Kei-Sing Tai, Paul Emery, Therapy Switching, Augmentation, and Discontinuation in Patients with Osteoarthritis and Chronic Low Back Pain Pain Practice. ,vol. 12, pp. 457- 468 ,(2012) , 10.1111/J.1533-2500.2011.00524.X
Bruce L. Kidd, Andrew Photiou, Julia J. Inglis, The role of inflammatory mediators on nociception and pain in arthritis. Novartis Foundation symposium. ,vol. 260, pp. 122- 138 ,(2004) , 10.1002/0470867639.CH9
Jie Shen, Jia Li, Baoli Wang, Hongting Jin, Meina Wang, Yejia Zhang, Yunzhi Yang, Hee-Jeong Im, Regis O'Keefe, Di Chen, Deletion of the transforming growth factor β receptor type II gene in articular chondrocytes leads to a progressive osteoarthritis-like phenotype in mice. Arthritis & Rheumatism. ,vol. 65, pp. 3107- 3119 ,(2013) , 10.1002/ART.38122
Peter S Tugwell, George A Wells, J Zev Shainhouse, Equivalence study of a topical diclofenac solution (pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. The Journal of Rheumatology. ,vol. 31, pp. 2002- 2012 ,(2004)
Philippe Goupille, Xavier Chevalier, Bruno Giraudeau, Thierry Conrozier, Jocelyne Marliere, Philippe Kiefer, Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. The Journal of Rheumatology. ,vol. 32, pp. 1317- 1323 ,(2005)